ReNeuron Group plc

Equities

RENE

GB00BF5G6K95

Biotechnology & Medical Research

Delayed London S.E. 09:30:01 2024-02-05 am EST 5-day change 1st Jan Change
3.375 GBX -2.17% Intraday chart for ReNeuron Group plc -.--% -3.57%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
ReNeuron appoints administrators as rescue talks fail AN
ReNeuron Group to Appoint Administrators MT
ReNeuron warns; Gama Aviation pledges cash return AN
ReNeuron Group Suspends Share Trading in London Amid Financial Woes MT
ReNeuron Group plc Provides Group Earnings Guidance for the Second Half and Full Year 2024 CI
ReNeuron interim loss narrows on lower costs; eyes partnerships AN
Earnings Flash (RENE.L) RENEURON GROUP Reports Fiscal H1 Revenue GBP157,000 MT
Earnings Flash (RENE.L) RENEURON GROUP Reports Fiscal H1 Loss GBX-5.00 MT
ReNeuron Group plc Reports Earnings Results for the Half Year Ended September 30, 2023 CI
ReNeuron Group Reports In Vivo Data for Exosome Delivery Platform MT
ReNeuron makes progress on exosome delivery platform AN
ReNeuron Group plc Auditor Raises 'Going Concern' Doubt CI
Transcript : ReNeuron Group plc, 2023 Earnings Call, May 25, 2023
Earnings Flash (RENE.L) RENEURON GROUP Posts FY23 Revenue GBP530,000 MT
Earnings Flash (RENE.L) RENEURON GROUP Posts FY23 Loss GBX-9.50 MT
ReNeuron Group plc Reports Earnings Results for the Full Year Ended March 31, 2023 CI
ReNeuron Group plc Announces New Scientific Advisory Board CI
FTSE 100 Closes Down 1.1% as Early Year Optimism Runs Into Turbulence DJ
ReNeuron reduces headcount by 40%; to focus on CustomEX data AN
Sterling Could Fall as BOE Stays Cautious DJ
UK House Prices Falling Faster than Expected - RICS DJ
UK Housebuilders Fall as Market Hits Weakest Since 2010 DJ
ReNeuron Cuts Headcount by 40%, Lowers Variable Costs in Restructuring Effort MT
FTSE 100 Falls After Losses on Wall Street DJ
FTSE 100 Closes Up 1.4% Lifted by Oil Sector DJ
Chart ReNeuron Group plc
More charts
ReNeuron Group plc is a United Kingdom-based Stem Cell and Exosome Technologies company that utilizes its stem cell technologies to develop treatments for disease with unmet needs. The Company has developed a proprietary stem cell-derived, exosome-based, drug delivery platform with customisable cellular targeting capabilities for the delivery of complex drug modalities. The Company's CustomEX platform can be optimised for specific tissues targets and payloads leading to improvements in therapeutic outcome and a reduction in off-target effects. The Company offers a delivery mechanism for a variety of payloads such as small interfering Ribonucleic Acid (siRNA), messenger RNA (mRNA), proteins, small molecules and genes. Through its conditionally immortalised induced pluripotent stem cell (iPSC) platform, the Company has the ability to make allogeneic tissue cells of choice and has the potential to produce exosomes with tissue specific targeting ability.
More about the company

Annual profits - Rate of surprise